{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:42:14Z","timestamp":1776440534520,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The evolution of ferritin levels in hepatitis C virus (HCV)-infected patients with sustained virological responses (SVRs) following various therapy regimens remains elusive. An 8-year prospective cohort study of 1194 HCV-infected patients [interferon-based therapy (n\u2009=\u2009620), direct-acting antiviral agent (DAA) therapy (n\u2009=\u2009355)] was conducted. At baseline, sex, alanine aminotransferase (ALT), triglycerides, homeostatic model assessment of insulin resistance (HOMA-IR), estimated glomerular filtration rate (eGFR), hemoglobin, iron\/total iron-binding capacity (Fe\/TIBC) and IFNL3-rs12979860 genotypes were associated with ferritin levels. At 24\u00a0weeks posttherapy, ALT, triglycerides, total cholesterol, eGFR, Fe\/TIBC and the therapy regimen were associated with ferritin levels in SVR patients. Among interferon-treated patients, ferritin levels increased at 24\u00a0weeks posttherapy, regardless of SVR, and 24-week posttherapy ferritin levels were higher in non-SVR patients (n\u2009=\u2009111) than in SVR patients (n\u2009=\u2009509); ferritin levels began decreasing at 3\u00a0years posttherapy and were lower than pretherapy levels since 4\u00a0years posttherapy in SVR patients. Among DAA-treated SVR patients (n\u2009=\u2009350), ferritin levels decreased and remained stable since 24\u00a0weeks posttherapy. ALT, triglycerides, eGFR, and Fe\/TIBC were HCV-unrelated factors associated with ferritin levels; sex, HOMA-IR, total cholesterol, hemoglobin and IFNL3-rs12979860 genotype were HCV-related factors associated with ferritin levels. In interferon-treated SVR patients, the increased trend of posttherapy ferritin levels was not reversed until 4\u00a0years posttherapy. In DAA-treated SVR patients, ferritin levels decreased since 24\u00a0weeks posttherapy.<\/jats:p>","DOI":"10.1038\/s41598-020-76871-z","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T11:02:41Z","timestamp":1605178961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evolution of ferritin levels in hepatitis C patients treated with antivirals"],"prefix":"10.1038","volume":"10","author":[{"given":"Ming-Ling","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Hong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Jung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiang-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"76871_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"CW Spearman","year":"2019","unstructured":"Spearman, C. W., Dusheiko, G. M., Hellard, M. & Sonderup, M. Hepatitis C. Lancet 394, 1451\u20131466 (2019).","journal-title":"Lancet"},{"key":"76871_CR2","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","volume":"218","author":"SM Borgia","year":"2018","unstructured":"Borgia, S. M. et al. Identification of a novel hepatitis C virus genotype from Punjab, India: Expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 218, 1722\u20131729 (2018).","journal-title":"J. Infect. Dis."},{"key":"76871_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/21505594.2016.1175700","volume":"7","author":"P Foka","year":"2016","unstructured":"Foka, P. et al. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency. Virulence 7, 679\u2013690 (2016).","journal-title":"Virulence"},{"key":"76871_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1086\/428062","volume":"40","author":"Y Shan","year":"2005","unstructured":"Shan, Y. et al. Association of hepatitis C virus infection with serum iron status: Analysis of data from the third National Health and Nutrition Examination Survey. Clin. Infect. Dis. 40, 834\u2013841 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"76871_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.4161\/viru.28508","volume":"5","author":"U Georgopoulou","year":"2014","unstructured":"Georgopoulou, U. et al. Hepcidin and the iron enigma in HCV infection. Virulence 5, 465\u2013476 (2014).","journal-title":"Virulence"},{"key":"76871_CR6","first-page":"187","volume":"5","author":"G Fiorelli","year":"2007","unstructured":"Fiorelli, G. Serum ferritin and erythrocyte indices in iron overload. Blood Transfus. 5, 187\u2013188 (2007).","journal-title":"Blood Transfus."},{"key":"76871_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/hep.22716","volume":"49","author":"RG Ruddell","year":"2009","unstructured":"Ruddell, R. G. et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta\/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49, 887\u2013900 (2009).","journal-title":"Hepatology"},{"key":"76871_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-2257.2002.0378a.x","volume":"24","author":"S Richard","year":"2002","unstructured":"Richard, S. & Billett, H. H. Liver function tests in sickle cell disease. Clin. Lab. Haematol. 24, 21\u201327 (2002).","journal-title":"Clin. Lab. Haematol."},{"key":"76871_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1053\/j.gastro.2007.10.011","volume":"134","author":"S Nishina","year":"2008","unstructured":"Nishina, S. et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134, 226\u2013238 (2008).","journal-title":"Gastroenterology"},{"key":"76871_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2893.2008.00972.x","volume":"15","author":"N Fujita","year":"2008","unstructured":"Fujita, N. et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J. Viral. Hepat. 15, 498\u2013507 (2008).","journal-title":"J. Viral. Hepat."},{"key":"76871_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.freeradbiomed.2006.11.001","volume":"42","author":"N Fujita","year":"2007","unstructured":"Fujita, N. et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic. Biol. Med. 42, 353\u2013362 (2007).","journal-title":"Free Radic. Biol. Med."},{"key":"76871_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/hep.24787","volume":"55","author":"CM Lange","year":"2012","unstructured":"Lange, C. M. et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 55, 1038\u20131047 (2012).","journal-title":"Hepatology"},{"key":"76871_CR13","first-page":"e13136","volume":"13","author":"C Vagu","year":"2013","unstructured":"Vagu, C. et al. Serum iron markers in patients with chronic hepatitis C infection. Hepat. Mon. 13, e13136 (2013).","journal-title":"Hepat. Mon."},{"key":"76871_CR14","first-page":"354","volume":"30","author":"EM Walker Jr","year":"2000","unstructured":"Walker, E. M. Jr. & Walker, S. M. Effects of iron overload on the immune system. Ann. Clin. Lab. Sci. 30, 354\u2013365 (2000).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"76871_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.0106-9543.2002.01672.x","volume":"22","author":"S Distante","year":"2002","unstructured":"Distante, S. et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 22, 269\u2013275 (2002).","journal-title":"Liver"},{"key":"76871_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3109\/00365548.2012.677545","volume":"44","author":"S Barut","year":"2012","unstructured":"Barut, S. et al. Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response. Scand. J. Infect. Dis. 44, 761\u2013765 (2012).","journal-title":"Scand. J. Infect. Dis."},{"key":"76871_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1440-1746.2004.03526.x","volume":"20","author":"S Hamamoto","year":"2005","unstructured":"Hamamoto, S. et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J. Gastroenterol. Hepatol. 20, 204\u2013208 (2005).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"76871_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.ai.2016.08.001","volume":"132","author":"JR Teijaro","year":"2016","unstructured":"Teijaro, J. R. Pleiotropic roles of type 1 interferons in antiviral immune responses. Adv. Immunol. 132, 135\u2013158 (2016).","journal-title":"Adv. Immunol."},{"key":"76871_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon, P. & Locarnini, S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55, 192\u2013206 (2011).","journal-title":"J. Hepatol."},{"key":"76871_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.blre.2008.08.001","volume":"23","author":"MA Knovich","year":"2009","unstructured":"Knovich, M. A. et al. Ferritin for the clinician. Blood Rev. 23, 95\u2013104 (2009).","journal-title":"Blood Rev."},{"key":"76871_CR21","doi-asserted-by":"publisher","first-page":"e104783","DOI":"10.1371\/journal.pone.0104783","volume":"9","author":"ML Chang","year":"2014","unstructured":"Chang, M. L. et al. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS ONE 9, e104783 (2014).","journal-title":"PLoS ONE"},{"key":"76871_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cmi.2019.06.018","volume":"26","author":"YT Cheng","year":"2020","unstructured":"Cheng, Y. T. et al. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: An 8-year prospective study. Clin. Microbiol. Infect. 26, 366\u2013372 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"76871_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10620-020-06507-9","volume":"1","author":"ML Chang","year":"2020","unstructured":"Chang, M. L. et al. Interactive impacts from hepatitis C virus infection and mixed cryoglobulinemia on complement levels. Dig. Dis. Sci. 1, 1. https:\/\/doi.org\/10.1007\/s10620-020-06507-9 (2020).","journal-title":"Dig. Dis. Sci."},{"key":"76871_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cgh.2014.10.023","volume":"13","author":"ML Chang","year":"2015","unstructured":"Chang, M. L., Jeng, W. J. & Liaw, Y. F. Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. Clin. Gastroenterol. Hepatol. 13, 979\u2013986 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"76871_CR25","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.3748\/wjg.v21.i11.3223","volume":"21","author":"MG Sanal","year":"2015","unstructured":"Sanal, M. G. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?. World J. Gastroenterol. 21, 3223\u20133231 (2015).","journal-title":"World J. Gastroenterol."},{"key":"76871_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2018.05.043","volume":"275","author":"MF Su\u00e1rez-Orteg\u00f3n","year":"2018","unstructured":"Su\u00e1rez-Orteg\u00f3n, M. F. et al. Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis. Atherosclerosis 275, 97\u2013106 (2018).","journal-title":"Atherosclerosis"},{"key":"76871_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fmed.2019.00303","volume":"6","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. Association between iron status and risk of chronic kidney disease in Chinese adults. Front. Med. (Lausanne) 6, 303 (2020).","journal-title":"Front. Med. (Lausanne)"},{"key":"76871_CR28","first-page":"108","volume":"20","author":"MJ Kotze","year":"2009","unstructured":"Kotze, M. J. et al. Pathogenic mechanisms underlying iron deficiency and iron overload: New insights for clinical application. EJIFCC 20, 108\u2013123 (2009).","journal-title":"EJIFCC"},{"key":"76871_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1440-1746.2004.03549.x","volume":"20","author":"IS Silva","year":"2005","unstructured":"Silva, I. S. et al. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J. Gastroenterol. Hepatol. 20, 243\u2013248 (2005).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"76871_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3892\/etm_00000109","volume":"1","author":"T Himoto","year":"2010","unstructured":"Himoto, T. et al. Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. Exp. Ther. Med. 1, 707\u2013711 (2010).","journal-title":"Exp. Ther. Med."},{"key":"76871_CR31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/j.1872-034X.2007.00152.x","volume":"37","author":"Y Sumida","year":"2007","unstructured":"Sumida, Y. et al. Hepatic iron accumulation may be associated with insulin resistance in patients with chronic hepatitis C. Hepatol. Res. 37, 932\u2013940 (2007).","journal-title":"Hepatol. Res."},{"key":"76871_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1034\/j.1600-0676.2003.00841.x","volume":"23","author":"M Furutani","year":"2003","unstructured":"Furutani, M. et al. YInsulin resistance\/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int. 23, 294\u2013299 (2003).","journal-title":"Liver Int."},{"key":"76871_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2036.2011.04903.x","volume":"35","author":"EW Hwang","year":"2012","unstructured":"Hwang, E. W. et al. Implications of rapid virological response in hepatitis C therapy in the US veteran population. Aliment. Pharmacol. Ther. 35, 105\u2013115 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"76871_CR34","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/j.1572-0241.2001.04053.x","volume":"96","author":"F Jorquera","year":"2001","unstructured":"Jorquera, F. et al. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy. Am. J. Gastroenterol. 96, 2456\u20132461 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"76871_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1572-0241.2008.01813.x","volume":"103","author":"S Petta","year":"2008","unstructured":"Petta, S. et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 103, 1136\u20131144 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"76871_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1440-1746.2010.06568.x","volume":"26","author":"Y Sumida","year":"2011","unstructured":"Sumida, Y. et al. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J. Gastroenterol. Hepatol. 26, 836\u2013842 (2011).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"76871_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2893.2005.00662.x","volume":"13","author":"G Sebastiani","year":"2006","unstructured":"Sebastiani, G. et al. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J. Viral. Hepat. 13, 199\u2013205 (2006).","journal-title":"J. Viral. Hepat."},{"key":"76871_CR38","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1021\/pr201128s","volume":"11","author":"C Mancone","year":"2012","unstructured":"Mancone, C. et al. Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J. Proteome. Res. 11, 2786\u20132797 (2012).","journal-title":"J. Proteome. Res."},{"key":"76871_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jceh.2017.06.002","volume":"8","author":"R Mehta","year":"2018","unstructured":"Mehta, R. et al. Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients. J. Clin. Exp. Hepatol. 8, 3\u20136 (2018).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"76871_CR40","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/ajh.24911","volume":"92","author":"R Origa","year":"2017","unstructured":"Origa, R. et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am. J. Hematol. 92, 1349\u20131355 (2017).","journal-title":"Am. J. Hematol."},{"key":"76871_CR41","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.2169\/internalmedicine.2909-19","volume":"58","author":"S IInomata","year":"2019","unstructured":"IInomata, S. et al. Changes in the serum hepcidin-to-ferritin ratio with erythroferrone after hepatitis C virus eradication using direct-acting antiviral agents. Intern. Med. 58, 2915\u20132922 (2019).","journal-title":"Intern. Med."},{"key":"76871_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","volume":"53","author":"JR Carvalho","year":"2018","unstructured":"Carvalho, J. R. et al. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication\u2014comparison of the new direct-acting antiviral agents with the old regimens. Scand. J. Gastroenterol. 53, 857\u2013863 (2018).","journal-title":"Scand. J. Gastroenterol."},{"key":"76871_CR43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2008.05.014","volume":"49","author":"N Fujita","year":"2008","unstructured":"Fujita, N. et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J. Hepatol. 49, 702\u2013710 (2008).","journal-title":"J. Hepatol."},{"key":"76871_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/apt.14197","volume":"46","author":"A Mangia","year":"2017","unstructured":"Mangia, A. et al. Randomised clinical trial: Sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment. Pharmacol. Ther. 46, 424\u2013431 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"76871_CR45","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/jmv.23632","volume":"85","author":"A Amanzada","year":"2013","unstructured":"Amanzada, A. et al. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. J. Med. Virol. 85, 1534\u20131541 (2013).","journal-title":"J. Med. Virol."},{"key":"76871_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4321\/S1130-01082009000100004","volume":"101","author":"JM Ladero","year":"2009","unstructured":"Ladero, J. M. et al. Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C. Rev. Esp. Enferm. Dig. 101, 31\u201340 (2009).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"76871_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000122604","volume":"1","author":"M Nagashima","year":"2008","unstructured":"Nagashima, M. et al. Elevated serum ALT levels during pegylated interferon monotherapy may be caused by hepatic iron overload. Intervirology 1, 76\u201385 (2008).","journal-title":"Intervirology"},{"key":"76871_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jmv.20323","volume":"76","author":"N Kamar","year":"2005","unstructured":"Kamar, N. et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J. Med. Virol. 76, 61\u201368 (2005).","journal-title":"J. Med. Virol."},{"key":"76871_CR49","doi-asserted-by":"publisher","first-page":"16184","DOI":"10.3748\/wjg.v20.i43.16184","volume":"20","author":"K Soota","year":"2014","unstructured":"Soota, K. & Maliakkal, B. Ribavirin induced hemolysis: A novel mechanism of action against chronic hepatitis C virus infection. World. J. Gastroenterol. 20, 16184\u201316190 (2014).","journal-title":"World. J. Gastroenterol."},{"key":"76871_CR50","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/hep.29685","volume":"67","author":"S Saab","year":"2018","unstructured":"Saab, S. et al. Toward the elimination of hepatitis C in the United States. Hepatology 67, 2449\u20132459 (2018).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76871-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76871-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76871-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:56:28Z","timestamp":1670367388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76871-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["76871"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-76871-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19744"}}